About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, October 15th, 2012

The QualityStocks
Daily Stock List


Mexus Gold US (MXSG)

SmallCapVoice, AllPennyStocks, 777 Stocks, Wall Street Reporter, FeedBlitz, OTC Picks and Stock Guru reported earlier on Mexus Gold US (MXSG), and we highlight the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in Carson City, Nevada, Mexus Gold US engages in the evaluation, acquisition, exploration, development and production of mining properties. They also conduct salvage operations for the recovery of precious metals. The Company engages in the mining industry for the purpose of producing precious metals, including gold, silver and copper, from their projects located in the state of Sonora, Mexico and in the states of Nevada and Alaska. Mexus Gold US lists on the OTCQB.
Mexus has been evaluating projects that they deem have very strong potential for further evaluation and future exploration. This process has resulted in the decision to enter into an agreement with Mexus Gold Mining S.A. DE C.V. This agreement will give Mexus Gold US the option to acquire 99 percent of the outstanding shares of Mexus Gold Mining, S.A. DE C.V. - located in the State of Sonora, Mexico.
Mexus Gold US's primary activities in the near future will consist of their mining operations in Nevada and Mexico and their cable salvage operations in Alaska and along the west coast of the United States. Their mining opportunities in the state of Nevada and the state of Sonora, Mexico will provide them with projects to recover gold, silver, copper, and other precious metals. The cable salvage opportunity involves principally the recovery of copper and lead from abandoned cable previously utilized for communications purposes.

Mexus produces gold daily at their Caborca placer mine site in Mexico. The Company's 300 ton per hour crushing plant is on site. The complete crushing and milling recovery plant is operational. Mexus is starting on the Julio vein system first. The Company continues to core drill on the Julio.

Last week, Mexus Gold announced that they received a geological report prepared by an independent geologist covering part of the Julio Property near the current placer plant and northward toward the Julio Vein. The property is on or near the Mojave-Sonora Mega Shear Zone, which is well known as a major source of gold bearing zones presently undergoing mining by a number of major gold production companies.

An initial group of 164 samples over a relatively small area of the Julio Property forms the basis for the report. The basis of a tentative tonnage estimate of 3,676,400 grams gold with a cutoff of one gram was on a study of six veins visible on the surface and located in parallel running southeast toward the northwest. The values of the samples ranged from 0.92 grams to 7.26 grams.

The Julio Vein extends over 800 meters before it buries. It is known for high bonanza grades, which includes the underground mining site on the property and is estimated at 415,000 tons on the surface with a minimum of 5 grams per ton. The report states that the vein is expected to become a combination open pit and underground operation upon further geological study and exploration activities. There are also four shear zones recognized in the area.

Mexus Gold US (MXSG), closed Monday's trading session at $0.37, up 32.14%, on 543,332 volume with 108 trades. The average volume for the last 60 days is 301,420 and the stock's 52-week low/high is $0.03/$0.475.

Integrated Management Information, Inc. (WFCF)

We are highlighting Integrated Management Information, Inc. (WFCF) today, here at the QualityStocks Daily Newsletter.

Integrated Management Information, Inc. (d.b.a. IMI Global) is America's leading provider of third-party identification, verification and traceability solutions for the livestock and agricultural industries. They support over 6,000 ranchers, feed yards, meatpackers, food retailers and restaurants with a broad array of solutions. Since 1995, IMI Global has worked with some of the largest agricultural organizations in the U.S. The Company provides comprehensive applications for verification and identification, and a range of consulting services tailored to meet each customer's needs. Integrated Management Information (IMI Global) lists on the OTCQB; the Company has their headquarters in Castle Rock, Colorado.

IMI Global solutions include their USVerified™ brand. This is the industry standard for USDA Process Verified (PVP) programs , which each year verifies marketing claims for approximately one half of all U.S. beef exports. The Company also has their Where Food Comes From® offering. This is a unique retail and restaurant-labeling program. It connects consumers directly to the source of the food they purchase.

IMI Global has a program developed specifically for each beef industry sector. They have services to fit the diverse needs of their clients. These include a specialty verification program for a client's calves, QSA program development, or a Country of Origin Affidavit.

IMI Global has assisted companies across the U.S. in building their own USDA Process Verified (PVP), Quality System Assessment (QSA) and Export Verification (EV) Programs. Of the approved USDA Process Verified Programs in existence, the Company has assisted more than 45 percent of those listed. Of the approved QSA programs listed, they have assisted more than 80 percent. Their clients include packers, further processors, cold storages, as well as exporting companies.

In August, Integrated Management Information (d.b.a. IMI Global) announced that Delmonico's, New York's oldest steakhouse and one of America's most renowned restaurants, would provide their patrons with the Where Food Comes From® solution for all of their beef menu offerings.

Delmonico's patrons, using their smart phones, can now scan the Quick Response (QR) bar code on the restaurant's menus to access information on the origin of the beef they order. This marketing program gives Delmonico's guests the opportunity to learn more about the producer representatives and production practices associated with the beef the restaurant serves their patrons.

Integrated Management Information, Inc. (WFCF), closed Monday's session at $1.55, up 3.33%, on 86,225 volume with 65 trades. The average volume for the last 60 days is 17,643 and the stock's 52-week low/high is $0.03/$1.59.

NeoStem, Inc. (NBS)

RedChip reported last week on NeoStem, Inc. (NBS), SmallCap Network, Buzz Stocks, Day Trade Alert, SmarTrend Newsletters, Greenbackers, StreetInsider, AllPennyStocks, Bull Warrior Stocks did earlier, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

NeoStem, Inc. is an emerging leader in the fast growing cell therapy market. Continuing to develop and build on their core capabilities in cell therapy, the Company's multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC (PCT), with a medically important cell therapy product development program. Their contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem has their corporate headquarters in New York, New York.

The Company's most clinically advanced therapeutic is AMR-001. It is undergoing development at Amorcyte, LLC (100 percent NeoStem owned) which NeoStem acquired in October of 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack.

Athelos Corp., approximately 80 percent-owned by NeoStem's subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. Additionally, pre-clinical assets include NeoStem's VSEL™ Technology (very small embryonic-like stem cells) platform and their mesenchymal stem cell product candidate for regenerative medicine - pluripotent adult stem cells that can regenerate tissues and potentially treat conditions ranging from macular degeneration to liver regeneration to osteoporosis (exclusive worldwide license).

NeoStem's service business and pipeline of proprietary cell therapy products work together. The Company acquired Progenitor Cell Therapy (PCT) to bring additional cell therapy expertise in house and to develop a "one-stop-shop" worldwide network of cell therapy.

Last week, NeoStem announced that data from their collaborative studies with the University of Michigan School of Dentistry further expands the therapeutic potential of their proprietary regenerative cell therapy product, VSEL™, by demonstrating bone regeneration capabilities in a study published online ahead of print in the journal Stem Cells and Development (DOI: 10.1089/scd.2012.0327). The paper highlights that human VSEL stem cells form human bone when implanted in the bone tissue of SCID mice.

Moreover, last week, NeoStem announced that a new article published by the International Scholarly Research Network provides further evidence that AMR-001, the Company's lead product candidate via their Amorcyte subsidiary, appears capable of preserving heart muscle function following a large myocardial infarction. Amorcyte demonstrated in their Phase 1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced deterioration in heart muscle function who received 10 million cells or more; 30 to 40 percent of patients not receiving a therapeutic dose did. The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown.

NeoStem, Inc. (NBS), closed Monday's trading at $0.7075, up 0.35%, on 1,089,086 volume with 1,016 trades. The average volume for the last 60 days is 1,145,646 and the stock's 52-week low/high is $0.30/$0.90.

FastFunds Financial Corp. (FFFC)

Top Best Pennystocks, SmallCapAllStars, VIP Penny Stocks, Momentum Hunter, MyBestStockAlerts, Cash Cow Stocks, Illuminati Stocks, Penny Stock Racer, Street Beat, Penny Stock Pulse, PremiereStockAlerts, 24-7 Stock Alert, and Penny Stock Explosion reported recently on FastFunds Financial Corp. (FFFC), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the Over-the-Counter QB, FastFunds Financial Corp. is a holding company in a number of business segments. The Company is currently seeking new business opportunities to diversify and complement their current services and products, and enhance their technical capabilities. FastFunds Financial currently operates in the financial services industry segment with a single credit card services portfolio. The Company is based in West Palm Beach, Florida.

Earlier, FastFunds Financial announced the formation of a new subsidiary, Advanced Technology Development, Inc. They also announced the acquisition of Carbon Capture USA, Inc. via their new subsidiary.  Carbon Capture USA has an exclusive U.S. license related to provisional patent Serial number 61/077,376 and a U.S. Patent to be issued.

The patent titled, "Method of Separating Carbon Dioxide", relates to methods of decomposing a gaseous medium. More precisely, it relates to methods of utilizing radio frequency energy to separate the elemental components of gases such as carbon dioxide. Advanced Technology Development will begin research and development with a goal of potential commercialization, subject to financing. In addition, FastFunds Financial's intention is to look for other business opportunities in natural resources and consumer products to expand their reach and diversify their business segments.

Last week, FastFunds Financial announced their development plans for their recently acquired carbon separation technology. The Company recently acquired 100 percent of the outstanding common stock of Carbon Capture USA, which holds the exclusive US license relating to provisional patent no. 61/077,376. The Company is in initial consultation with the principal inventor. This consultation relates to the best path to commercialization. The anticipation is that there will be initial research and development, development of a proof of concept prototype and the seeking of interested third parties for financing and commercialization.

Furthermore, last week, FastFunds Financial announced that they signed a Letter of Intent (LOI) to acquire a 40 percent interest in a gold mining property (the Camanti Project) located in Quince Mil, District of Camanti, Province of Quispicanchis, Department of Cusco, near the border of Madre de Dios, in Peru. This ownership interest will be in the form of a Joint Venture (JV) with Affinity Gold, Inc., the owner of the mineral lease agreement and operator. The property consists of 850 hectares (approximately 1,700 acres).

FastFunds Financial Corp. (FFFC), closed Monday's trading session at $0.012, off by 25.00%, on 1,014,426 volume with 50 trades. The average volume for the last 60 days is 325,676 and the stock's 52-week low/high is $0.005/$0.20.

GBS Enterprises, Inc. (GBSX)

SmallCap Fortunes and SmallCapVoice reported earlier on GBS Enterprises, Inc. (GBSX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, GBS Enterprises, Inc. is a leader in Application Modernization Technology and Cloud Services. In addition, the Company is the world's leading provider of expertise for the IBM Lotus Notes/Domino platform. GBS has more than 5,000 customers with more than 4 million users of their products and services. The Company's resources are available at over 15 offices across North America, Europe and Asia. GBS Enterprises has their North American headquarters in Atlanta, Georgia, and their European headquarters in Frankfurt, Germany.

GBS helps customers understand and evaluate their current Lotus infrastructure and application environments, formulate strategic technology and operational goals, and implement solutions that meet current and future business needs. The Company conducts their primary business via their 50.1 percent-owned subsidiary, GROUP Business Software AG (GROUP), a German-based public company.

GROUP's software and consulting business concentrates on serving IBM's Lotus Notes and Domino market. GROUP caters primarily to mid-market and enterprise-size organizations. GROUP's customers include Abbot, Ernst & Young, Deutsche Bank, Bayer, HBSC, Merck and Toyota. GROUP provides IBM Lotus Notes/Domino Application and Transformation technology, and related Cloud Computing technology.

GBS Enterprises has achieved significant growth by consolidating the fragmented Lotus Software market through the merger & acquisitions of companies with complementary product, technology or services offerings. GBS has continuously developed their software and service business to service and support their expanding Lotus customer base.

Going forward, the Company will focus on potential acquisition targets in the following areas of software and services: Applications, Professional Services, Hosting/Outsourcing Services, Administration and IT services, and XPages expertise. GBS's recent acquisitions have led to consolidated solutions and resources that will further the Company's mission to reduce corporate IT spending by enabling all Lotus applications internally or externally to run in a self-service fashion by the year 2014. GBS Enterprises generates their revenue from the sale of software developed by the Company and third parties and delivery of related services. This includes Information Technology (IT) systems planning, administration, support, hosting, implementation and integration.

GBS Enterprises, Inc. (GBSX), closed Monday's trading session at $0.25, up 13.64%, on 25,000 volume with 2 trades. The average volume for the last 60 days is 15,366 and the stock's 52-week low/high is $0.20/$2.61.

Gleacher & Company, Inc. (GLCH)

AllPennyStocks, OTCPicks, The Momentum Traders Network, The Street, Hit and Run Candle Sticks, and smallcap360 reported earlier on Gleacher & Company, Inc. (GLCH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the NASDAQ Global Select market, Gleacher & Company, Inc. is an independent investment bank. They provide corporate and institutional clients with strategic and financial advisory services, including merger and acquisition, restructuring, recapitalization, and strategic alternative analysis, and capital raising, research based investment analysis, and securities brokerage services. In addition, via a new subsidiary, they engage in residential mortgage lending. Gleacher & Company is headquartered in New York, New York.

The Company is a full service investment bank. Eric Gleacher leads Gleacher & Company's investment banking advisory group. He is former head of Worldwide Mergers and Acquisitions at Morgan Stanley and founder of the Mergers and Acquisitions Department at Lehman Brothers.

As pertains to Sales & Trading, the Company is a leading provider of sales and trading execution services on a broad spectrum of debt and equity securities to corporate and institutional investors. Concerning Research, Gleacher & Company provides unbiased, insightful and timely equity and fixed income research for institutional investors across a number of industry sectors.
Gleacher & Company's Fixed Income platform provides structured finance, research, sales, and trading services on a broad array of fixed income products. These include mortgage and asset-backed securities, U.S. Treasury and government agency securities, structured products such as CLOs and CDOs, as well as high yield, investment grade and emerging markets credit products. The Company has strong relationships with institutional investors, including mutual funds, pension funds, insurance companies, hedge funds, investment managers and investment advisors, by providing value-added investment ideas and access to execution services and inventory capital.

At the end of August, Gleacher & Company announced that they retained a financial advisor to assist the Company in exploring and evaluating strategic alternatives. They, to further their strategic plan, intend to consider a range of available options, including partnering with one or more equity investors, strategic acquisitions and divestitures, and a business combination involving the Company. Gleacher & Company has not made any decision to engage in any specific alternative at this time, and the exploration of strategic alternatives may not result in any specific action or transaction.

In late September, Gleacher & Company Securities, Inc., a broker-dealer subsidiary of Gleacher & Company, announced that Mark Ginsberg and Felix Partow joined the firm as Managing Directors in the MBS & Rates Division, and William Gaberlavage and Jeffrey Warren joined as Managing Directors in the Credit Products Division. All four are located in Gleacher & Company's New York Office.

Gleacher & Company, Inc. (GLCH), closed Monday’s session at $0.69, down 0.01%, on 17,257 volume with 57 trades. The average volume for the last 60 days is 172,878 and the stock's 52-week low/high is $0.53/$1.88.

Empowered Products, Inc. (EMPO)

Pumps and Dumps, Hot Stock Profits, Wyatt Investment Research, Bird Gang Stocks, Club Penny Stocks Network, OTCPicks, PennyTrader Publisher, Stockdigest Report, StockRunway, TooNiceStocks, Penny Stock Explosion, and Winning Penny Stock Picks reported last week on Empowered Products, Inc. (EMPO). Today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Empowered Products, Inc. has a leading presence in the worldwide wellness industry. The Company has developed, manufactured, and now distributes 17 high quality wellness products. Currently, their products are available at more than 3,000 retail locations in more than 30 countries spanning four continents. Empowered Products has their headquarters in Las Vegas, Nevada. The Company's shares trade on the OTCQB.

By way of their select marketing and sponsorship endeavors, Empowered Products is steadily establishing strong brand awareness for their PINK® and Gun-Oil® lines of sexual lubricants and libido enhancing supplements. In 2012, the Company has had over 200,000 direct consumers sign-on to their online venues and product storefronts. These include www.EmpoweredProducts.com, www.PinkforUs.com, and www.GunOil.com. Empowered Products objective is to garner 1 million direct consumer sign-ups by the mid-point of 2013.

The Company offers a line of topical gels, lotions, and oils. These are formulated to increase mental focus and improve the bond of interpersonal relationships. They market their products through a network of distributors, wholesalers, pharmacies, and chain and online retailers in North America, Europe, and Asia; as well as sells directly to retail consumers through their online store. Empowered Products provides products for men under the aforementioned Gun-Oil ® trademark and products for women under the aforementioned PINK® trademark.

Last week, Empowered Products announced that they received their first purchase order from TARGET.com, a division of the Target Corporation, dated October 8, 2012. This initial order includes both PINK and Gun-Oil silicone and water-based personal lubricants as well as the hybrid lubricants, PINK Indulgence and Gun-Oil Loaded.

Mr. Scott Fraser, President and Chief Executive Officer of Empowered Products, commented, "Our new sales relationship with Target is an important milestone in our continued expansion into national retailers, such as Walgreens and CVS, from our original sales channel in adult-product venues that we established over 10 years ago. Our move to the mainstream is a cornerstone of our long term growth for Empowered Products and our EMPO shareholders."

Empowered Products, Inc. (EMPO), closed Monday's trading session at $1.01, up 4.12%, on 54,968 volume with 58 trades. The average volume for the last 60 days is 10,053 and the stock's 52-week low/high is $0.65/$1.32.

Noront Resources Ltd. (NOT.V)

Streetwise Reports and AllPennyStocks reported earlier on Noront Resources Ltd. (NOT.V), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Noront Resources Ltd. engages in the acquisition, exploration, and development of mineral properties in Canada. They concentrate on developing the high-grade Eagle's Nest nickel-copper-platinum-palladium deposit, the exploration and development of the Blackbird chromite discovery, and regional exploration for additional mineral deposits within their large, highly prospective land position in the "Ring of Fire", an emerging multi-metals camp located in the James Bay Lowlands of Ontario. Noront Resources lists on the TSX Venture Exchange and on the OTC Pink Current Information under the trading symbol NOSOF. The Company has their headquarters in Toronto, Ontario.

Noront discovered, in 2007, a nickel, copper, platinum and palladium discovery at the deposit now known as Eagle's Nest. Since that initial discovery, the Company has made additional discoveries including the Blackbird chromite deposits; Eagle Two, a nickel, copper discovery; AT-12, a nickel, copper, platinum and palladium discovery; Thunderbird, a vanadium, iron, titanium deposit, and the Triple J Gold Zone.

Noront Resources is advancing the Eagle's Nest project development and performing exploration drilling at the Eagle's Nest Complex to identify new Ni-Cu sulphide deposits. In addition, the Company is performing additional drilling on the Blackbird chromite deposits, advancing the development of the Blackbird chromite deposits through additional technical studies, performing a complete analysis of AT-12 data to define and prioritize targets, and performing on-going reviewing and prioritization of additional regional exploration. In fiscal 2012, Noront's intention is to spend approximately $15 million dollars on these objectives.

In September, Noront Resources announced the results of an updated National Instrument 43-101 - Standards of Disclosure for Mineral Projects (NI 43-101) compliant Feasibility Study (FS) for a stand alone nickel, copper, platinum group element (Ni-Cu-PGE) mine and mill complex exploiting their 100 percent owned Eagle's Nest deposit, McFaulds Lake, James Bay Lowlands, Ontario. The results of the independent study, completed by Independent Consultants under the supervision of Micon International, confirm that Eagle's Nest offers robust economics.

The Company's McFaulds Lake Project is in the highly prospective Ring of Fire multi metals district in the James Bay lowlands of northern Ontario. Noront, with more than 117,000 hectares of mineral claims, is the largest exploration claim holder in this new exploration district.

Noront Resources Ltd. (NOT.V), closed Monday's trading session at $0.345, up 1.47%, on 86,981 volume. The stock's 52-week low/high is $0.34/$0.94.


The QualityStocks
Company Corner


Loans4Less.com, Inc. (LFLS)

The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.08, up 68.42%, on 124,090 volume with 25 trades. The stock’s average daily volume over the past 60 days is 10,023, and its 52-week low/high is $0.01/$0.51.

Loans4Less.com, Inc. reported preliminary Q3 results today (period ending Sept 30), including a year-over-year increase of quarterly revenues by 56% and an estimated 437% increase in net income. The company also anticipates a significant improvement to the overall balance sheet, with the mortgage origination market remaining strong throughout the rest of this year. Loans4Less believes highly favorable market conditions will enable ongoing significant improvement in its business growth and future expansion.

Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.

Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.

The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.

Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer

Loans4Less.com, Inc. Company Blog

Loans4Less.com, Inc. News:

Loans4Less.com Provides Preliminary Financial Results for the Third Quarter of 2012

Loans4Less.com, Inc. New Audio Interview With Chairman and CEO Steven M. Hershman

Loans4Less.com, Inc. Announces Engagement of QualityStocks Investor Relations Services.

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.01, up 185.71%, on 886,000 volume with 17 trades. The stock’s average daily volume over the past 60 days is 170,916, and its 52-week low/high is $0.001/$0.018.

Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.

Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.

In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming

Consorteum Completes Acquisition of Tarsin Inc.

Teletouch Communications, Inc. (TLLE)

The QualityStocks Daily Newsletter would like to spotlight Teletouch Communications, Inc. (TLLE). Today, Teletouch Communications, Inc. closed trading at $0.50, up 4.17%, on 45,480 volume with 16 trades. The stock’s average daily volume over the past 60 days is 25,524, and its 52-week low/high is $0.253/$0.89.

Teletouch Communications, Inc. (TLLE) offers a comprehensive suite of wireless telecommunications solutions, including cellular, GPS-telemetry, and wireless messaging. Founded in 1964, the company provides its products and services to consumers, businesses, and government agencies, operating a chain of 11 retail and authorized agent stores, in conjunction with its direct sales force, call center operations, and various retail eCommerce websites.

Through its wholly owned subsidiary, Progressive Concepts, Teletouch operates a national distribution business, PCI Wholesale, primarily serving Tier-1 (AT&T, T-Mobile, Verizon, Sprint) cellular carrier agents, Tier-2, Tier-3, and rural carriers, as well as auto dealers and smaller consumer electronics retailers. The subsidiary's international sales coverage includes Canada, Mexico, Brazil, Singapore, and China.

The company is currently focusing on growing its core wholesale distribution business. The business plan being executed includes selling non-core corporate assets and reviewing potential acquisition opportunities. Operators and retailers of all sizes are seeking new sources of revenue at lower costs, creating a large opportunity to provide great products and value-added distribution capabilities at competitive prices.

Teletouch's management team has extensive experience in financing, acquiring, and operating retail, wireless and other related companies. Robert McMurrey, Chairman and CEO, guided Teletouch's original external expansion with the completion of over 15 acquisitions to date. Today, the company supports over 60,000 wireless customers, leveraging its long-standing relationships and global presence to drive future earnings growth. Disclaimer

Teletouch Communications, Inc. Blog

Teletouch Communications, Inc. News:

Teletouch Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl

Teletouch Announces Distribution Agreement with Unimax Communications for Sales of UMX Branded Cellular Handsets in North America

Teletouch Reports Fiscal Year 2012 Results

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.75, up 12.61%, on 1,200 volume with 3 trades. The stock’s average daily volume over the past 60 days is 168, and its 52-week low/high is $0.06/$3.15.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund

VistaGen CEO Issues Update Letter to Stockholders

VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity

Loans4Less.com, Inc. (LFLS) Anticipates Reporting 437% Gain in Net Income, Revenues Up 56%

Loans4Less.com today reported certain preliminary financial results for the third quarter ended September 30, 2012. According to today’s press release, the complete 2012 third quarter financial results will be posted in due course.

Revenues for the third quarter of 2012 are expected to be approximately 56% higher than the numbers reported for the third quarter of 2011. Third quarter net income is anticipated to be 437% greater compared to the same period a year earlier. Preliminary results also indicate that there will be a substantial improvement in the balance sheet.

Loans4Less.com believes the mortgage origination market will stay very active for the remainder of 2012 even though lender underwriting standards are enabling only best credit quality borrowers to close on their loans. The current mortgage market mainly consists of Fannie Mae/Freddie Mac Conforming fixed rate loans for refinancings.

Steven M. Hershman, Chairman & President, stated, “Purchase activity is gaining traction with mortgage rates at record lows. Loans4Less.com sees highly favorable market conditions as a catalyst for ongoing significant improvement in our business growth and future expansion.”

Q3 2012 Income Statement versus Q3 2011
Revenues $730K versus $468K + 56%
Net Income $258K versus $48K +437%

Q3 2012 Balance Sheet versus Q3 2011
Cash $72.5K versus $8K
Total Liabilities $79.4K versus $206.6K

Common Stock Outstanding
30,550,000 versus 31,155,000

Public Float
3,157,981 versus 2,115,078

For more information, visit www.Loans4Less.com

Teletouch Communications, Inc. (TLLE) Focused on Consumer Communications Wholesale Distribution

Teletouch Communications, a Texas-based communications and consumer electronics company, has two primary business segments:

Hawk Electronics
(retail, direct, and online sale of communications and other electronic equipment)

- 16 retail and authorized agent stores serving the Texas area
- Proprietary billing and CRM platform
- In-house technical support and call center

PCI Wholesale
(wireless products distribution to carrier agents, rural carriers, resellers, and other wholesale distributors, plus wholesale distribution to retail, sub-distribution, and large accounts)

- National and international sales to markets, including Canada, Mexico, Brazil, UK, Sinapore, and China
- Representing JVC, Sony, Magellan, Motorola, LG, Nokia, Acer, Samsung, Blackberry, Alcatel, and many more

The company’s goals for 2013 are to continue its ongoing transition to a core wholesale distribution business, focused on the following products and technologies:

• Alcatel One Touch – Branded Cellular Handsets
• Monster Digital – SD and Micro SD Cards
• Boston Amplifier – Wireless Signal Boosters
• Aerovoice/Concept 101 – ATT Branded Consumer Electronics
• PureGear – Wireless Accessories
• Parrot – Bluetooth Accessories
• Wilson Electronics – Cellular Signal Boosters
• Cellphone Mate – Cellular Signal Boosters

Teletouch has signed a number of distribution agreements, most recently announcing their first direct handset manufacturing distribution agreement with TCT Mobile, maker of the Alcatel OneTouch cellular handsets and part of one of the largest consumer manufacturing companies in the world.

To learn more about Teletouch, visit www.teletouch.com

Cardium Therapeutics, Inc. (CXM) Written Up by Major Biotech Publisher

A recent article in Genetic Engineering & Biotechnology News, the world’s number one biotech publisher, carried a good report on Cardium Therapeutics and Generx, a Cardium product candidate. Generx is a DNA-based angiogenic growth factor therapeutic used to stimulate the growth of supplemental collateral blood vessels in the hearts of patients with advanced coronary artery disease. Superior to medicines that only provide transient relief of symptoms, Generx is designed to actually enhance myocardial blood flow in heart patients without having to resort to invasive surgical procedures. Availability of such a treatment option is especially important in many parts of the world where more elaborate procedures are not readily available or affordable.

The article explains how patients with coronary artery disease (angina) have had the Generx Ad5FGF-4 vector infused into their coronary arteries. Cardium researchers found that patients with more severe coronary artery disease responded better than those with less severe disease. The fact that a medicine’s effectiveness increases with the severity of disease might be considered encouraging, but researchers wanted to know why this was happening. They found that multiple blockages in a coronary artery, like a prolonged blockage, causes vasodilation, exposing more vessels and more surface area, along with increased vessel permeability. This allows enhanced Generx uptake, increasing its effectiveness. More importantly, the Coxsackie Adenovirus Receptor (CAR), normally buried in the tight junction, is exposed.

Gabor Rubanyi, M.D., Ph.D., and CSO of Cardium Therapeutics, summarized the finding: “When there is ischemia or any injury, then these tight junctions loosen up and these proteins all of a sudden are exposed and can bind the virus. Transfection starts with adenovirus fiber protein attaching to this receptor.”

It’s a good example of Cardium’s ongoing efforts to understand the underlying nature of genes and the human body, allowing improvements and new discoveries that continue to drive the company’s progress.

For additional information, visit www.CardiumTHX.com

GreeneStone Healthcare Corp. (GRST) Helps the Bottom Line of Corporate Clients

Based in Toronto, healthcare provider GreeneStone focuses much of its services on the mental health of employees for its growing list of corporate clients. These services include treatment programs for addiction, eating disorders, and other mental health issues that are now being recognized as significantly detrimental to a company’s bottom line. Up-front investment in evaluating and treating mental and emotional conditions is increasingly being seen as a wise business decision. It’s a movement picking up steam in both the U.S. and Canada, as gathering statistics point to the seriousness of the problem.

In Canada alone, where GreeneStone has all of its treatment facilities, the productivity loss resulting from workplace mental health disorders is estimated to be approximately $20 billion. One survey indicates that roughly 14% of employees say they have been diagnosed as suffering from depression. The Canadian government has now put together a national standard for evaluating the psychological health and safety of the workplace, primarily to help concerned company’s assess hazards and measure the effectiveness of associated programs.

These growing concerns and efforts mesh closely with GreeneStone’s stated mission: To be the trusted partner to organizations and their executive workforce by providing executives with seamless access to the health and performance professionals they need, when they need it, to perform at their best in the workplace. GreeneStone provides treatment and services in addiction, eating disorders, and other areas of mental health, as well as in cardiology, diabetes, endoscopy, nutrition, weight loss, and more. The idea is to provide companies and employees a coordinated, personalized, one-stop care system that meets a full range of mental and physical needs. Instead of leaving it up to individuals to search out and coordinate healthcare services on their own, GreeneStone offers an integrated case-worker managed system that makes getting the right care far easier and better organized.

It’s an approach that has also worked for GreeneStone’s bottom line, giving the company positive revenue growth over the past seven quarters.

For additional information, visit the company’s websites at www.GreeneStoneClinic.com and www.GreeneStoneInvestor.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Penny Stock Racer



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251